Medpace

MEDP

Market cap $12.7B

LOS ANGELES, June 02, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming June 8, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Medpace Holdings, Inc. (“Medpace” or the “Company”) (NASDAQ: MEDP) common stock between April 22, 2025 and February 9, 2026, inclusive (the “Class Period”).

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Medpace To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Medpace between April 22, 2025 and February 9, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - June 2, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Medpace Holdings, Inc. ("Medpace" or the "Company") (NASDAQ: MEDP) and reminds investors of the June 8, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Medpace Holdings, Inc. (NASDAQ: MEDP) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Medpace securities between April 22, 2025 and February 9, 2026, both dates inclusive (the “Class Period”).

LOS ANGELES, June 02, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Medpace Holdings, Inc., (“Medpace” or the "Company") (NASDAQ: MEDP) investors of a class action on behalf of investors that bought securities between April 22, 2025 and February 9, 2026, inclusive (the “Class Period”). Medpace investors have until June 8, 2026 to file a lead plaintiff motion.

NEW YORK, June 2, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Medpace Holdings, Inc. (NASDAQ: MEDP). Shareholders who purchased shares of MEDP during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

NEW YORK, June 01, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Medpace Holdings, Inc. (NASDAQ: MEDP) between April 22, 2025 and February 9, 2026, inclusive (the “Class Period”), of the important June 8, 2026 lead plaintiff deadline.

The trading activity of members of Congress continues to be closely monitored by investors, especially when the moves include Magnificent Seven or large technology stocks. One member of Congress recently sold some Magnificent Seven stocks.

NEW YORK, June 1, 2026 /PRNewswire/ --  Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Medpace Holdings, Inc. (NASDAQ: MEDP) between April 22, 2025 and February 9, 2026, inclusive (the "Class Period"), of the important June 8, 2026 lead plaintiff deadline. So what: If you purchased Medpace common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Deadline Alert: Understanding Lead Plaintiff Selection Under the PSLRA Deadline Alert: Understanding Lead Plaintiff Selection Under the PSLRA

New York, New York--(Newsfile Corp. - June 1, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Medpace Holdings, Inc. (NASDAQ: MEDP) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Medpace securities between April 22, 2025 and February 9, 2026, both dates inclusive (the "Class Period").